<DOC>
	<DOC>NCT00094484</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).</brief_summary>
	<brief_title>Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Chronic Kidney Disease patients not receiving dialysis with: An iPTH greater than 100 pg/mL [10.6 pmol/L] for subjects with stage 3 CKD or greater than or equal to 160 pg/mL [17.0 pmol/L] for subjects with stage 4 CKD; A serum calcium greater than 9.0 mg/dL [2.25 mmol/L]; An estimated GFR less than or equal to 59 mL/min and greater than or equal to 15 mL/min. Have an unstable medical condition, defined as having been hospitalized within 30 days before day 1, or otherwise unstable in the judgment of the investigator. Experienced a myocardial infarction (MI) within 3 months before day 1. Likely to initiate dialysis (in the opinion of the investigator) or are scheduled to undergo renal transplantation within 28 weeks after day 1. Received active vitamin D therapy (i.e., 1hydroxylated metabolites of vitamin D) for less than 30 days before day 1 or required a change in active vitamin D brand or dose level within 30 days before day 1 (for patients prescribed active vitamin D).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sensipar®</keyword>
	<keyword>Mimpara®</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>Calcimimetic</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>